Market Research Logo
Region: Africa
Category: Life Sciences

Africa Life Sciences

(657 reports matching your criteria)
  • Namibia Pharmaceuticals & Healthcare Q4 2018

    ... and efficiency issues within the public healthcare sector. The small middle-and upper-class segments provide pockets of demand for innovative medicines, which will continue to be imported by key regionalplayers and representative offices of established multinationals. Read More

  • Zimbabwe Pharmaceuticals & Healthcare Q4 2018

    ... multinational drugmakers are deterred by thechallenging macroeconomic environment. Achieving self-sufficiency in the sector will require currency regime reform; however, itremains unclear which new regime they will adopt. This creates uncertain conditions in Zimbabwe's pharmaceutical market ... Read More

  • Gabon Pharmaceuticals & Healthcare Q4 2018

    ... by factors including modest but growingpopulation numbers, high prevalence of infectious diseases and the growing burden of civilisation diseases. However, given thetight funding environment, most of the commercial opportunities remain limited to the generics sector. Read More

  • Tunisia Pharmaceuticals & Healthcare Q4 2018

    ... will challenge foreign investment into the sector.Highlighting the market's longer-term potential, some multinational drugmakers have shown their willingness to do business in thecountry, though the majority choose to operate indirectly to minimise the risks involved. Read More

  • Kenya Medical Devices Q4 2018

    ... the Kenyan shilling. The market will remain heavily reliant onimports due to domestic manufacturers focusing on basic consumables. The Equitable Division of Revenue Bill and ambitions ofachieving universal healthcare coverage will benefit medical device manufacturers. Read More

  • Sub-Saharan Africa Medical Devices Q4 2018

    ... GDP growth reading reflecting that it has entered into a technical recession,poses downside risks. The SSA market will remain heavily reliant on imports and international aid and funding, thereforemultinationals will continue to strengthen their presence. ... Read More

  • South Africa Medical Devices Q4 2018

    ... GDP growth reading reflecting that South Africa has entered into atechnical recession as the economy recorded two consecutive quarters of negative growth. However, the establishment of theSouth African Health Products Regulatory Authority (SAHPRA), which will ... Read More

  • Botswana Pharmaceuticals & Healthcare Q4 2018

    ... healthcare. Medicine sales will be limited by weakregulatory framework, a small pensionable population and a highly ruralised community. Despite a potential for growth in theunderdeveloped sector, multinational drugmakers will favour larger markets in the region ... Read More

  • Nigeria Pharmaceuticals & Healthcare Q4 2018

    ... opportunities are supported by robust fundamentals such as a large market size and expandingpopulation. The majority of multinational drugmakers will continue to opt for an indirect presence as the business climate remainsdecidedly difficult in Nigeria. Read More

  • South Africa Pharmaceuticals & Healthcare Q4 2018

    ... in the wider economy. This will shape opportunities for domestic and foreigndrugmakers. While we expect the South African government to prioritise the local generic drug industry, opportunities formultinational firms producing patented medicines will remain abundant. Read More

  • Mauritius Pharmaceuticals & Healthcare Q4 2018

    ... moderately greater spending power than its peers in Sub-SaharanAfrica, Mauritius’ per capita medicine expenditure will remain well below the purchasing power of developed markets. On the upside,the business environment will remain relatively strong, while Mauritius' ... Read More

  • Mozambique Pharmaceuticals & Healthcare Q4 2018

    ... diseases and improving the country'soverall health standing, poor regulatory framework and a fragmented healthcare system will limit patient access to qualitymedicines. Furthermore, ongoing political and economic risks cause us to view Mozambique as one of ... Read More

  • Morocco Pharmaceuticals & Healthcare Q4 2018

    ... treatments. Although the government'scommitment to improving healthcare via the expansion of health insurance coverage will be a significant factor for future medicinesales growth, we believe generics drugmakers will be the main beneficiaries as the state ... Read More

  • Tanzania Pharmaceuticals & Healthcare Q4 2018

    ... limited by low per capita spending on medicines andan underdeveloped healthcare sector. Whilst demand for medicine will increase over the long-term, driven by the country’s rapidlyexpanding population and high disease burden, we expect that Tanzania's ... Read More

  • Zambia Pharmaceuticals & Healthcare Q4 2018

    ... low purchasing power and theprevalence of counterfeit medicines. On the other hand, authorities' support for the reduction of reliance on pharmaceuticalimports and the encouragement of public-private healthcare delivery partnerships have already begun to attract foreign ... Read More

  • Ghana Medical Devices Q4 2018

    ... local currency and US dollar termsover the 2017-2022 period. Relatively strong economic growth, the large population and ongoing healthcare projects will benefitthe market, but decreasing health expenditure and limited domestic production will constrain market growth. Read More

  • Ethiopia Pharmaceuticals & Healthcare Q4 2018

    ... government is strongly committed to improvingthe operating environment to attract foreign investment, particularly from China, which combined with a budding manufacturingsector bodes well for foreign drugmaker appetite. Over the near-term, multinational drugmaker investment in the ... Read More

  • Angola Pharmaceuticals & Healthcare Q4 2018

    ... training doctors and nurses, weakening the pharmaceutical andhealthcare sectors. Angola’s new President, João Lourenço, has pledged to combat corruption, attract foreign investment andimprove healthcare services. However, we continue to view Angola as one of the ... Read More

  • Sudan and South Sudan Pharmaceuticals & Healthcare Q4 2018

    ... of commercial incentives limit multinational drugmaker interest in the market.Positive fundamentals in the form of a rising chronic disease burden and large population bode well for long-term opportunities,however, the elevated industry-and-operational risks will undermine any ... Read More

  • Cameroon Pharmaceuticals & Healthcare Q4 2018

    ... underpin rising spending on healthcare and pharmaceuticals.That said, low purchasing power and a poor operating environment will weigh on opportunities for drugmakers. Meanwhile, as themarket develops, local drug manufacturers will expand from a small base. Read More

  • CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Morocco

    ... information and analysis on the healthcare, regulatory and reimbursement landscape in Morocco. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Morocco. ... Read More

  • Egypt Medical Devices Q4 2018

    ... there is enormous potential for growth as the country has the largest population in the Arabworld. Improving political and economic fundamentals will support long-term market growth, following recent economic turbulenceand the massive depreciation of the ... Read More

  • Generics in South Africa

    ... of the leading players including key financial metrics and analysis of competitive pressures within the market. Synopsis Essential resource for top-line data and analysis covering the South Africa generics market. Includes market size data, textual ... Read More

  • Nigeria Medical Devices Q4 2018

    ... market will benefit from an improved outlook for the economy and will remainalmost entirely reliant on imports. The large population and highly underdeveloped healthcare sector offer huge long-termpotential, but chronic underfunding and the chaotic management ... Read More

  • Cote d'Ivoire Pharmaceuticals & Healthcare Q4 2018

    ... advantage, key factors such as limited access tomedicines and a lack of healthcare infrastructure will limit commercial opportunities. We hold a more positive long-term outlook onthe back of economic prosperity and the push for healthcare ... Read More

< prev 1 3 4 5 6 7 8 9 10